SPY304.28-0.04 -0.01%
DIA253.63-0.66 -0.26%
IXIC9,506.37+16.50 0.17%

H.C. Wainwright Reiterates Neutral on Aimmune Therapeutics, Lowers Price Target to $15

H.C. Wainwright analyst Andrew Fein reiterates Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and lowers the price target from $30 to $15.

Benzinga · 05/12/2020 12:00

H.C. Wainwright analyst Andrew Fein reiterates Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and lowers the price target from $30 to $15.